SLNO Soleno Therapeutics Inc

$68.57

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending —
Expected on —
Report Time: Unknown Release Time
The Whisper Number
—
Consensus Estimate: —
Revenue Estimate: —

Latest Earnings Insight

Updated On 8/22/2025

About Soleno Therapeutics Inc

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapies for the treatment of rare diseases. The company is headquartered in Redwood City, California.

Website: https://soleno.life

Sector
LIFE SCIENCES
Industry
ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS
Exchange
NASDAQ
Country
USA
Currency
USD
Fiscal Year End
December
CIK
1484565
Address
1235 RADIO ROAD, SUITE 110, REDWOOD CITY, CA, US
Valuation
Market Cap
$3.21B
P/E Ratio
nan
PEG Ratio
0.00
Price to Book
13.09
Performance
EPS
$-4.38
Dividend Yield
—
Profit Margin
0.00%
ROE
-87.40%
Technicals
50D MA
$54.36
200D MA
$50.71
52W High
$74.00
52W Low
$36.93
Fundamentals
Shares Outstanding
46M
Target Price
$102.12
Beta
-2.29

SLNO EPS Estimates vs Actual

● Estimated
● Actual

SLNO News & Sentiment

Aug 19, 2025 • Benzinga NEUTRAL
INVESTOR ALERT: Investigation of Soleno Therapeutics, Inc. ( SLNO ) Announced by Holzer & Holzer, LLC - Soleno Therapeutics ( NASDAQ:SLNO )
ATLANTA, Aug. 19, 2025 ( GLOBE NEWSWIRE ) -- Holzer & Holzer, LLC is investigating whether Soleno Therapeutics, Inc. ( "Soleno Therapeutics" or the "Company" ) SLNO complied with federal securities laws.
Aug 19, 2025 • Zacks Commentary SOMEWHAT-BULLISH
Down 21.7% in 4 Weeks, Here's Why Soleno Therapeutics ( SLNO ) Looks Ripe for a Turnaround
The heavy selling pressure might have exhausted for Soleno Therapeutics (SLNO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend ...
Aug 19, 2025 • Benzinga NEUTRAL
Soleno Therapeutics ( SLNO ) Drops Amid Critical Scorpion Report -- Hagens Berman - Soleno Therapeutics ( NASDAQ:SLNO )
SAN FRANCISCO, Aug. 19, 2025 ( GLOBE NEWSWIRE ) -- On August 15, 2025, shares in Soleno Therapeutics, Inc. SLNO experienced a significant drop following the release of a highly critical report by Scorpion Capital. Hagens Berman, a national shareholders rights firm, has opened an investigation ...
Aug 15, 2025 • Benzinga NEUTRAL
Soleno Under Serious Scrutiny As Short Seller Alleges PWS Drug Is Overpriced, Unsafe - Soleno Therapeutics ( NASDAQ:SLNO )
SLNO shares fall 9.68% after Scorpion Capital calls Vykat XR unsafe and overpriced. The report warns that Soleno's stock could drop back to penny-stock territory. Get the latest proven ETF strategies to target and profit from summer volatility before the next big market swing.
Aug 11, 2025 • Zacks Commentary SOMEWHAT-BULLISH
How Much Upside is Left in Soleno Therapeutics ( SLNO ) ? Wall Street Analysts Think 43.15%
The average of price targets set by Wall Street analysts indicates a potential upside of 43.2% in Soleno Therapeutics (SLNO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Aug 11, 2025 • Zacks Commentary BULLISH
Here's Why Momentum in Soleno Therapeutics ( SLNO ) Should Keep going
Soleno Therapeutics (SLNO) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Sentiment Snapshot

Average Sentiment Score:

0.206
50 articles with scored sentiment

Overall Sentiment:

Bullish

SLNO Reported Earnings

Mar 04, 2025
Dec 31, 2024 (Pre market)
-0.19 Surprise
  • Reported EPS: $-1.27
  • Estimate: $-1.08
  • Whisper: —
  • Surprise %: -17.9%
Nov 05, 2024
Sep 30, 2024 (Pre market)
-1.2 Surprise
  • Reported EPS: $-1.83
  • Estimate: $-0.63
  • Whisper: —
  • Surprise %: -190.5%
Aug 07, 2024
Jun 30, 2024 (Post market)
0.03 Surprise
  • Reported EPS: $-0.57
  • Estimate: $-0.60
  • Whisper: —
  • Surprise %: 5.0%
May 09, 2024
Mar 31, 2024 (Post market)
-0.22 Surprise
  • Reported EPS: $-0.59
  • Estimate: $-0.37
  • Whisper: —
  • Surprise %: -59.5%
Mar 06, 2024
Dec 31, 2023 (Post market)
-0.06 Surprise
  • Reported EPS: $-0.33
  • Estimate: $-0.27
  • Whisper: —
  • Surprise %: -22.2%
Nov 07, 2023
Sep 30, 2023 (Pre market)
-0.37 Surprise
  • Reported EPS: $-0.95
  • Estimate: $-0.58
  • Whisper: —
  • Surprise %: -63.8%
Aug 08, 2023
Jun 30, 2023 (Post market)
0.02 Surprise
  • Reported EPS: $-0.81
  • Estimate: $-0.83
  • Whisper: —
  • Surprise %: 2.4%
May 09, 2023
Mar 31, 2023 (Post market)
-0.16 Surprise
  • Reported EPS: $-0.88
  • Estimate: $-0.72
  • Whisper: —
  • Surprise %: -22.2%
Mar 21, 2023
Dec 31, 2022 (Post market)
0.22 Surprise
  • Reported EPS: $-0.58
  • Estimate: $-0.80
  • Whisper: —
  • Surprise %: 27.5%

Financials